The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comorbidity, metastases, and survival in women with metastatic breast cancer (mBC) receiving HER2-targeted agents (H2Ts).
Nicole Meyer
Research Funding - Truven Health Analytics
Yanni Hao
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Xue Song
Research Funding - Truven Health Analytics
William M. Johnson
Research Funding - Truven Health Analytics
Nianwen Shi
Research Funding - Truven Health Analytics
Jaqueline Willemann Rogerio
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Denise A. Yardley
No relevant relationships to disclose